Skip to main content
logo
Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
65.26
-0.06 (-0.09%)
Oct 9, 2025, 4:00 PM EDT - Market closed

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212014 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2014 - 2020
United States Revenue
781.99M697.16M
Log In
Log In
Log In
Upgrade
International Revenue
46.86M41.85M
Log In
Log In
Log In
Upgrade
Revenue (Total)
-739.02M
Log In
Log In
Log In
Upgrade

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212014 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2014 - 2020
Revenue (Other)
-739.02M
Log In
Log In
Log In
Upgrade
Revenue (Total)
-739.02M
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212014 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2014 - 2020
Precision Oncology Testing Revenue
-687.94M
Log In
Log In
Log In
Upgrade
Development Services and Other Revenue
-51.08M
Log In
Log In
Log In
Upgrade
Revenue (Total)
-739.02M
Log In
Log In
Log In
Upgrade

Gross Profit

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212014 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2014 - 2020
Precision Oncology Testing Gross Profit
-427.36M
Log In
Log In
Log In
Upgrade
Development Services and Other Gross Profit
-21.86M
Log In
Log In
Log In
Upgrade
Gross Profit (Total)
-449.22M
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212014 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2014 - 2020
Clinical Test Sales Volume
233.40K206.70K
Log In
Log In
Log In
Upgrade
Biopharmaceutical Test Sales Volume
-40.50K
Log In
Log In
Log In
Upgrade
Updated Jul 30, 2025. Data Source: Fiscal.ai.